Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.

Background: Pediatric infections caused by resistant Gram-positive infections are an increasing concern with limited treatment options. Linezolid, a new oxazolidinone, is active against staphylococci, streptococci and enterococci.

Objective: To assess clinical efficacy and safety of linezolid vs.